Value in Oncology, an Interview with Marty Neltner

C. Ola Landgren, MD, PhD, and Noopur Raje, MD, discussed results from the ADVANCE trial of DKRd in patients with newly diagnosed multiple myeloma.

Daniel C. McFarland, DO, and Michelle B. Riba, MD, spoke about distress screening and integrating psychosocial care into oncology.

Data from the phase 1/2 GO29781 study support the approval of subcutaneous mosunetuzumab in this follicular lymphoma population.

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

Pooled analysis data from the phase 1 JSKN003-101 and phase 1/2 JSKN003-102 trials support the regulatory decision.

“VIKTORIA-1 is the first study to demonstrate a statistically significant and clinically meaningful improvement in PFS with PAM inhibition in patients with PIK3CA wild-type disease, all of whom received prior CDK4/6 inhibition,” said Barbara Pistilli, MD.